Asosiy kontentga oʻtish
Sharh maqola

Label‑Free Optical Biosensing of Interleukin‑6, Procalcitonin, and High‐Sensitivity C‐Reactive Protein as Inflammatory Biomarkers in Cardiovascular Disease: A Review

Ghada Al-AssiFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman JordanWaleed K. AbdulsahibDepartment of Pharmacology and Toxicology, College of Pharmacy Al Farahidi University Baghdad IraqSanan Thaer Abdal-WahabDepartment of Medical Laboratory Techniques Al‐Turath University Baghdad IraqG. Padma PriyaDepartment of Chemistry and Biochemistry, School of Sciences JAIN (Deemed to Be University) Bangalore Karnataka IndiaPusparaj SamantsingharDepartment of Forensic Medicine & Toxicology IMS and SUM Hospital, Siksha ‘O’ Anusandhan Bhubaneswar Odisha IndiaJ. PremkumarDepartment of Biomedical Sathyabama Institute of Science and Technology Chennai Tamil Nadu IndiaGunjan MukherjeeUniversity Institute of Biotechnology Chandigarh University Mohali Punjab IndiaAashna SinhaSchool of Applied and Life Sciences, Division of Research and Innovation Uttaranchal University Dehradun Uttarakhand IndiaNigora TukhtaevaDepartment of Internal Diseases Propedeutics #2 Tashkent State Medical University Tashkent Uzbekistan
2026en
ABI

Annotatsiya

Cardiovascular disease (CVD) is closely related to inflammation, but traditional laboratory methods are too slow for use during acute cardiac treatment. Label‑free optical biosensors, specifically surface plasmon resonance (SPR) and fiber‑optic sensors, provide rapid detection of low‑abundance biomolecules. We will review three biomarkers that can be used in combination to assess inflammation status (interleukin 6), bacterial infection status (procalcitonin), and chronic risk of future CVD (high sensitivity C-reactive protein). Development of new materials for use as transducers, new biorecognition elements, and new microsystems will be highlighted along with challenges associated with those developments including problems associated with specific biological matrices, issues related to scalability of production of devices, and regulatory concerns. Clinically, a portable optical biosensor designed to measure the three biomarkers from a drop of blood taken from a finger would allow for differentiation between sterile inflammation and infective endocarditis, guidance regarding appropriate use of antibiotics, and stratification of long term risk for developing CVD at the bedside. This review demonstrates that optical biosensing technology and clinical needs are aligned for developing personalized point‑of‑care diagnostic systems in CVD.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar